Additionally, we highlight the miR-30d-5p/SIRT1/PGC-1α axis as a central pathway mediating these beneficial effects, suggesting that miR-30d-5p may serve as a potential therapeutic target for improving metabolic health in T2DM. The gene discussed is SIRT1; the disease is type 2 diabetes mellitus.